TALIUS GROUP LIMITED — Board/Management Information 2020

Nov 3, 2020

==> picture [596 x 101] intentionally omitted <==

HSC appoints Advisory Board to bolster Company expertise and guide growth

4 November 2020

• HSC strategic review identified opportunities to improve the value and performance of the Company

• Advisory Board established to take advantage of external expertise

• Two key international finance and healthcare industry executives with extensive experience appointed

HSC Technology Group Ltd (ASX:HSC) (“HSC” or the “Company”) is pleased to announce it has appointed two international finance and healthcare industry executives to its Advisory Board to assist in the growth of the Company and improve its value and performance.

Eugene Lim and Martin Robinson will take up the roles after HSC determined to implement a number of operational and other enhancements, including the establishment of the Advisory Board.

Mr Lim is a former Managing Director at Credit Suisse (Asia) where he was employed for over 19 years including roles as CEO of Credit Suisse Securities Singapore, responsible for overseeing all equities securities business conducted in the country, and head of ASEAN Equity Sales, responsible for managing the equity distribution business in all ASEAN offices. His positions included being a conduit between Capital Markets and Corporate Finance teams on numerous transactions and public offerings in the region. For the past six years he has advised on private equity transactions in the Asia Pacific region for family offices and wealth management companies.

Mr Robinson has over 20 years of growth and private equity investing, C-suite, investment committee, corporate finance and legal experience including over US$2 billion of healthcare investments/exits across Asia, Australia, Africa and the Middle East since 2010. He is a founding partner of HEAL Partners, a health, education and lifestyle growth stage private equity fund. He previously led the healthcare private equity strategy for a multi-billion dollar private investment group based in Singapore, originating and leading the US$123 million acquisition of Hoan My Medical Corporation, and as Chairman, led the transformation of the group into Vietnam’s leading hospital network. He also originated and led the Series A round investment into HaloDoc, Indonesia’s leading health tech mobile platform and was a Board member.

Mr Robinson previously worked for the Religare/Fortis Healthcare Group in Singapore where he was responsible for several landmark healthcare principal investments across Asia-Pacific including the acquisition of Quality Healthcare Hong Kong, Radlink Singapore and the takeover of Dental Corp Australia. He also spent five years with Macquarie Bank (Australia & Hong Kong), where he was responsible for the Group’s Asian principal investments and Head of Sponsor Coverage Asia.

Managing Director, Graham Russell, said HSC was excited to welcome the calibre and experience of Mr Lim and Mr Robinson to their Advisory Board and looked forward to working with them to grow value for the Company.

“The Advisory Board has been established to provide guidance, advice and networking assistance to the HSC Board and senior management of the Company in respect of our business and operations,” he said.

“The counsel we are seeking includes the identification, analysis and management of opportunities and risks and the full range of commercial, political, legal and other issues which could have a material influence on the Company’s ability to successfully achieve our vision of becoming the industry leader.

“Our focus is to provide a world class proprietary data analytics platform that utilises a range of globally sourced IoT enabled devices and sensors to deliver decision-making insights to clients, their families and medical practitioners to ultimately improve people’s safety, independence, autonomy and most importantly improve their lives.

==> picture [596 x 76] intentionally omitted <==

1

==> picture [596 x 101] intentionally omitted <==

“We are confident that both Mr Lim’s and Mr Robinson’s extensive experience in the finance and healthcare fields will help drive this, and their appointment bolsters our management and executive team to one of the most qualified in our industry.”

This announcement has been authorised by the Board of Directors of HSC Technology Group Ltd.

Investor Enquiries Marcus Fraumano Joint Company Secretary investors@hsctg.com.au

About HSC Technology Group

HSC provides a range of Connected Health and Smart Home solutions

The HSC assistive technology platforms allow seniors and people with disabilities to live independently via “Ageing in Place” solutions, through the use of data analysis, as well as human monitoring, to determine residents’ routines and detect anomalies. These early insights allow for better decision-making by care providers and families, allowing more focused service, minimising unnecessary care and facilitating welfare checks in a more responsive manner.

HSC helps protect and connect our elderly and people with disabilities with a scalable healthcare technology platform integrated with leading third party providers to ensure end-to-end solutions for Connected health.

HSC Technology Group’s Software as a Service (SaaS) data analytics platform TALIUS uses next generation Machine Learning and Artificial Intelligence to deliver decision-making insights that improves people’s safety, independence, autonomy and most importantly improves their lives.

• HSC Care + HSC Home

• TALIUS

FORWARD LOOKING STATEMENTS

Certain statements contained in this ASX release, including information as to the future financial or operating performance of the Company and its projects, are forward looking statements. Such forward looking statements:

• (a) are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies;

• (b) involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward looking statements; and

(c) may include, among other things, statements regarding estimates and assumptions in respect of prices, costs, results and capital expenditure, and are or may be based on assumptions and estimates related to future technical, economic, market, political, social and other conditions. The Company disclaims any intent or obligation to publicly update any forward-looking statements, whether as a result of new information, future events or results or otherwise. The words “believe”, “expect”, "contracted”, “anticipate”, “indicate”, “contemplate”, “target”, “plan”, “intends”, “continue”, “budget”, “estimate”, “may”, “will”, “schedule”, “planned” and similar expressions identify forward looking statements. All forward looking statements contained in this ASX release are qualified by the foregoing cautionary statements. Recipients are cautioned that forward looking statements are not guarantees of future performance and accordingly recipients are cautioned not to put undue reliance on forward looking statements due to the inherent uncertainty therein.

==> picture [596 x 76] intentionally omitted <==

2